Novartis plans to acquire clinical stage biotech Regulus Therapeutics in a deal worth up to $1.7 billion. Under the terms announced April 30, the Swiss drugmaker will make an upfront payment of $800 ...

It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the ...

(Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments ...

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of ...

Swiss pharmaceutical giant Novartis AG (NVS) has agreed to acquire American biotech firm Avidity Biosciences (RNA) for roughly $12 billion in an all-cash deal. Novartis will pay Avidity shareholders ...

Swiss pharma giant Novartis AG NVS reported core earnings per share (excluding one-time charges) of $2.25 in the third quarter, which missed the Zacks Consensus Estimate by a penny. Nonetheless, the ...

Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a ...

Detailed price information for Avidity Biosciences Inc (RNA-Q) from The Globe and Mail including charting and trades.